Sleep, Circadian Disruption And Neurocognition In Breast Cancer (Bc) Patients Undergoing Chemotherapy.

10072 Background: Up to 70% of cancer patients report cancer-related cognitive impairments (CRCI) during chemotherapy. Good sleep quality and robust circadian rhythmicity are possible modifiable factors for management of CRCI during treatment and the survivorship phase. We tested the relationships between sleep, circadian rest-activity rhythm and CRCI in patients with BC. Methods: 40 Patients (50 years, SD = 11; 53% White, 28% Asian, 19% Other) with primary BC (18% Stage I, 50% Stage II, 33% Stage III) undergoing chemotherapy completed the following neurocognitive battery: Hopkins Verbal Learning Test (assesses verbal memory and learning), Controlled Oral Word Association Test (verbal fluency), and Comprehensive Trail-Making Test (executive function, attention and processing speed). In addition, participants wore a wrist-actigraph (Actiwatch 2; Phillips Respironics) over 7 consecutive days for measuring circadian function (estimated with the dichotomy index I < O), and completed self-report questionnaires of sleep (Pittsburg Sleep Quality Index [PSQI], Insomnia Severity Index [ISI]), fatigue (Brief Fatigue Inventory [BFI]), and depression and anxiety (Clinical Assessment of Depression [CAD]). Results: Better circadian function (higher dichotomy index) was associated with less sleep disruption (PSQI, r = -.44, p = .005) and less insomnia (ISI, r = -.42, p = .008). Both subjective sleep alteration and circadian disruption were associated with significantly higher levels of fatigue (BFI, all p-values < .05) and sleep disruption measures were strongly associated with higher levels of depression and anxiety (ISI: r = .51, p = .001; PSQI: r = .43, p = .005). There were no significant associations found between circadian and sleep disruption variables and neurocognitive measures (p > .05). Consistent with prior studies, no associations were found between CAD and neurocognitive measures (p > .05). Conclusions: These preliminary data suggest that CRCI during chemotherapy might not be associated with either sleep or circadian disruption. It will be important to assess these variables later in the treatment and survivorship course when CRCI tends to become intractable or even progressive in some patients. Clinical trial information: NCT02165839.